Vima Therapeutics
vimatx.com
Actively hiring
Professional Services
Health Care
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$60M
1 round on record
Latest round
$60M
Series A · May 2025 · 16 mo ago
Backers
1
Atlas Venture
The money's age
Due for its next round
16 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
May 31, 2025
Raised a round Series A $60M · led by Atlas Venture · Pulse 2.0
May 29, 2025
Launched Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders · The Manila Times
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series A | May 2025 | $60M | Atlas Venture lead, Access Industries, Canaan | Pulse 2.0 |
Backed byfrom the funds' portfolios and accelerator catalogs
Atlas Venture Similar startupsby what they do, their industry and backers
Kailera is a late clinical-stage biotechnology company advancing a diversified pipeline of GLP-1 therapies to provide options for people…
Diagonal Therapeutics pioneers a new era in medicine by advancing clustering antibody therapeutics targeting the root causes of devastating…
We are building a quantum computer with scalability at its heart. Trapped-ion qubits with freedom to move and connect.
Synlogic is the leading company advancing therapeutics based on synthetic biology, working at the intersection of biology and engineering…
Access helps more than 100,000 customers transform the way their business software is used, giving every employee the freedom to do more of…
Croft is the all-in-one platform for compliant, streamlined H-2A - upholding your freedom to choose the Agents & Recruiters you trust.
News
Axios Pro Premium: Venture Capital News
The post Axios Pro Premium: Venture Capital News appeared first on Vima Therapeutics.
Read more
Report
With $100M, Vima pursues an oral drug for movement disorders
The post With $100M, Vima pursues an oral drug for movement disorders appeared first on Vima Therapeutics.
Read more
Report
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson's Disease
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson's diseaseFirst person has been dosed in Stride Dystonia trial, and Compan
Read more
Report
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson's Disease
New $40 million raise brings Series A total to $100M, enabling advancement of VIM0423, a first-in-class oral therapeutic, into Phase 2 trials for isolated dystonia and for Parkinson's diseaseFirst person has been dosed in Stride Dystonia trial, and Compan
Read more
Report
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson's Disease
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson's Disease
Read more
Report
Vima Therapeutics Announces First Dystonia Patient Dosed in Phase 2 Study and Extension of Series A to $100 Million to Advance Potential First-in-Class Oral Therapy for Dystonia and Parkinson's Disease
CAMBRIDGE, Mass., March 11, 2026 - Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced the first person dosed in a Phase 2 clinical trial in isolated dystonia with VIM0423, a potentia
Read more
Report
With $100M, Vima pursues an oral drug for movement disorders
Incubated by Atlas Venture, the biotech startup is advancing a daily pill it sees potentially helping people with dystonia or Parkinson's disease regain control of movement.
Read more
Report
Vima Therapeutics Announces First Dystonia Patient Dosed In Phase 2 Study And Extension Of Series A To $100 Million To Advance Potential First-In-Class Oral Therapy For Dystonia And Parkinson
Vima Therapeutics Announces First Dystonia Patient Dosed In Phase 2 Study And Extension Of Series A To $100 Million To Advance Potential First-In-Class Oral Therapy For Dystonia And Parkinson
Read more
Report
Emerging From Stealth With Vima Therapeutics' Bernard Ravina, MD
The post Emerging From Stealth With Vima Therapeutics' Bernard Ravina, MD appeared first on Vima Therapeutics.
Read more
Report
Show more news
Financials
Total raised
$60M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2025 | $60M | Details |